@article{44be37fa894d49d78f849704084638e8,
title = "A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer",
keywords = "Biomarkers, Breast cancer, Companion diagnostic, Metastasis, PD-L1, Tumor mutation burden",
author = "Geetha Jagannathan and White, {Marissa J.} and Xian, {Rena R.} and Emens, {Leisha A.} and Ashley Cimino-Mathews",
note = "Funding Information: G. Jagannathan: None; M.J. White: None; R.R. Xian: None; L.A. Emens: honoraria from AbbVie, Amgen, Celgene, Chugai, GCPR, Gilead, Gritstone, MedImmune, Peregrine, Shionogi, and Syndax; honoraria and travel support from AstraZeneca, Bayer, MacroGenics, Replimune, and Vaccinex; travel support from Bristol Myers Squibb, Genentech/Roche, and Novartis; potential future stock from Molecuvax; institutional support from AbbVie , Aduro Biotech , AstraZeneca , the Breast Cancer Research Foundation , Bristol Myers Squibb , Bolt Therapeutics , Compugen , Corvus , CyTomX , the US Department of Defense , EMD Serono , Genentech , Maxcyte , Merck , the National Cancer Institute , the NSABP Foundation , SU2C , Silverback , Roche , the Translational Breast Cancer Research Consortium , Takeda , Tempest , and HeritX ; royalties from Aduro Biotech; A. Cimino-Mathews: Research grants to institution from Bristol-Myers Squibb; consultancy/honoraria to self from Bristol-Myers Squibb and Roche.",
year = "2022",
month = mar,
doi = "10.1016/j.path.2021.11.007",
language = "English (US)",
volume = "15",
pages = "105--120",
journal = "Surgical Pathology Clinics",
issn = "1875-9181",
publisher = "W.B. Saunders Ltd",
number = "1",
}